应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
01093 石药集团
休市中 02-28 16:08:03
4.710
-0.280
-5.61%
最高
5.000
最低
4.670
成交量
1.60亿
今开
5.000
昨收
4.990
日振幅
6.61%
总市值
543.72亿
流通市值
543.72亿
总股本
115.44亿
成交额
7.60亿
换手率
1.38%
流通股本
115.44亿
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
数据加载中...
北京优虎网络科技有限公司
免责声明:香港交易所资讯服务有限公司、其控股公司及/或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度,但不能保证其绝对准确和可靠,且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任(不管是否侵权法下的责任或合约责任又或其它责任)
资讯
新帖
简况
石药集团只能往外跑了
财讯先锋 · 00:30
石药集团只能往外跑了
石药集团:注射用西罗莫司(白蛋白结合型)于中国获突破性治疗认定
格隆汇资讯 · 02-28 10:00
石药集团:注射用西罗莫司(白蛋白结合型)于中国获突破性治疗认定
石药集团(01093):注射用西罗莫司(白蛋白结合型)于中国获突破性治疗认定
智通财经 · 02-28 10:00
石药集团(01093):注射用西罗莫司(白蛋白结合型)于中国获突破性治疗认定
【石药集团:注射用西罗莫司(白蛋白结合型)获突破性治疗认定】石药集团公告,集团开发的注射用西罗莫司(白蛋白结合型)获国家药品监督管理局授予突破性治疗认定,拟定适应症为单药用于恶性血管周围上皮样细胞瘤。该产品采用特殊技术将西罗莫司包裹于人血白蛋白中,克服口服制剂无法向靶部位递送足够浓度药量的缺点,实现了西罗莫司的注射给药,且无需激素预处理。同时,该产品拓展了西罗莫司的应用领域,有望实现治疗mTOR信号通路驱动的一系列疾病。
金融界 · 02-28 09:56
【石药集团:注射用西罗莫司(白蛋白结合型)获突破性治疗认定】石药集团公告,集团开发的注射用西罗莫司(白蛋白结合型)获国家药品监督管理局授予突破性治疗认定,拟定适应症为单药用于恶性血管周围上皮样细胞瘤。该产品采用特殊技术将西罗莫司包裹于人血白蛋白中,克服口服制剂无法向靶部位递送足够浓度药量的缺点,实现了西罗莫司的注射给药,且无需激素预处理。同时,该产品拓展了西罗莫司的应用领域,有望实现治疗mTOR信号通路驱动的一系列疾病。
石药集团02月28日主力净流出5972万元 散户资金买入
市场透视 · 02-28 08:15
石药集团02月28日主力净流出5972万元 散户资金买入
港股异动 | 石药集团(01093)跌超4% 预计去年纯利同比减少约26% 多家大行下调其目标价
智通财经 · 02-28 03:57
港股异动 | 石药集团(01093)跌超4% 预计去年纯利同比减少约26% 多家大行下调其目标价
石药,遇到一个瓶颈
瞪羚社 · 02-27 12:08
石药,遇到一个瓶颈
美银证券:维持石药集团“跑输大市”评级 降目标价至4港元
和讯网 · 02-27 09:38
美银证券:维持石药集团“跑输大市”评级 降目标价至4港元
美银证券:维持石药集团(01093)“跑输大市”评级 降目标价至4港元
智通财经 · 02-27 08:56
美银证券:维持石药集团(01093)“跑输大市”评级 降目标价至4港元
港股异动 | 石药集团(01093)反弹近4% 大摩指其盈警对股价影响不大 看好今年新药销售业务
智通财经 · 02-27 07:29
港股异动 | 石药集团(01093)反弹近4% 大摩指其盈警对股价影响不大 看好今年新药销售业务
【大行评级|美银:下调石药集团目标价至4港元 销售增长在药品减价中受压】美银指,石药集团发盈警,预计去年纯利跌约26%,对比该行预测跌8%,扣除预付款影响则按年跌18%。成药销售按年跌约7%,对比该行预估的扣除预付款后跌9%。公司称收入及净利润下跌主要由津优力及多美素于京津冀3+N联盟药品集采中价格下跌,以及玄宁没有在国家第八批集采中中选,导致抗癌治疗及心向管治疗领域收入按年跌28%及15%。 该行指,多美素去年12月于国家第十批集采中中选,但面临另一轮减价。在去年国家报销药品清单磋商中,丁苯(酉太)注射及胶囊价格跌12.5%及3.6%,石药内生销售增长将面对进一步压力。该行调整对石药2024年至2026年收入预测,介乎下调1%至上调3%。同时上调去年及今年纯利预测19%及1%,但下调明年纯利预测12%。该行将其目标价由4.1港元降至4港元,维持“跑输大市”评级,基于主要产品减价影响。
金融界 · 02-27 05:55
【大行评级|美银:下调石药集团目标价至4港元 销售增长在药品减价中受压】美银指,石药集团发盈警,预计去年纯利跌约26%,对比该行预测跌8%,扣除预付款影响则按年跌18%。成药销售按年跌约7%,对比该行预估的扣除预付款后跌9%。公司称收入及净利润下跌主要由津优力及多美素于京津冀3+N联盟药品集采中价格下跌,以及玄宁没有在国家第八批集采中中选,导致抗癌治疗及心向管治疗领域收入按年跌28%及15%。 该行指,多美素去年12月于国家第十批集采中中选,但面临另一轮减价。在去年国家报销药品清单磋商中,丁苯(酉太)注射及胶囊价格跌12.5%及3.6%,石药内生销售增长将面对进一步压力。该行调整对石药2024年至2026年收入预测,介乎下调1%至上调3%。同时上调去年及今年纯利预测19%及1%,但下调明年纯利预测12%。该行将其目标价由4.1港元降至4港元,维持“跑输大市”评级,基于主要产品减价影响。
石药集团深陷困境,业绩大幅下滑,股价承压
新浪财经 · 02-27
石药集团深陷困境,业绩大幅下滑,股价承压
利润缩水近三成,石药如何挺过转型阵痛?
医药魔方 · 02-26
利润缩水近三成,石药如何挺过转型阵痛?
港股收评:恒指收涨3.27% 中资券商股飙升
美港电讯 · 02-26
港股收评:恒指收涨3.27% 中资券商股飙升
港股收盘,恒指收涨3.27%,科指收涨4.47%;中金(03908.HK)、中国银河(06881.HK)均涨超17%,龙湖集团(00960.
美港电讯 · 02-26
港股收盘,恒指收涨3.27%,科指收涨4.47%;中金(03908.HK)、中国银河(06881.HK)均涨超17%,龙湖集团(00960.
石药集团(1093.HK)盈警:预期2024年公司拥有人应占溢利同比减少约26%
IR之家 · 02-26
石药集团(1093.HK)盈警:预期2024年公司拥有人应占溢利同比减少约26%
野村:维持石药集团(01093)“买入”评级 降目标价至6.48港元
智通财经 · 02-26
野村:维持石药集团(01093)“买入”评级 降目标价至6.48港元
摩根士丹利:石药集团发盈警对股价影响不大 目标价6.8港元
美港电讯 · 02-26
摩根士丹利:石药集团发盈警对股价影响不大 目标价6.8港元
野村下调石药目标价至6.48港元 上调2025财年盈测
美港电讯 · 02-26
野村下调石药目标价至6.48港元 上调2025财年盈测
石药集团预计去年溢利减少约26%
新京报 · 02-26
石药集团预计去年溢利减少约26%
加载更多
公司概况
公司名称:
石药集团
所属市场:
SEHK
上市日期:
--
主营业务:
石药集团有限公司是一家主要从事生产及销售药品的投资控股公司。该公司通过三个分部运营其业务。成药分部从事研发、生产及销售药品以及授权业务。原料产品分部从事生产及销售粉状维生素C及抗生素产品。功能食品及其他分部从事制造及销售功能食品产品(包括咖啡因食物添加剂、无水葡萄糖、阿卡波糖及维生素C含片)、提供医疗服务及其他。该公司的产品治疗领域包括神经系统、抗肿瘤、抗感染、心血管、呼吸系统、消化代谢等其他领域。该公司在国内和国外市场开展业务。
发行价格:
--
{"stockData":{"symbol":"01093","market":"HK","secType":"STK","nameCN":"石药集团","latestPrice":4.71,"timestamp":1740730083029,"preClose":4.99,"halted":0,"volume":159783507,"delay":0,"floatShares":11544000000,"shares":11544000000,"eps":0.5275450516510444,"marketStatus":"休市中","change":-0.28,"latestTime":"02-28 16:08:03","open":5,"high":5,"low":4.67,"amount":760063507,"amplitude":0.066132,"askPrice":4.71,"askSize":2902000,"bidPrice":4.7,"bidSize":1424000,"shortable":3,"etf":0,"ttmEps":0.46561234024347553,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1740965400000},"marketStatusCode":7,"adr":0,"listingDate":772128000000,"exchange":"SEHK","adjPreClose":4.99,"dividendRate":0.060713,"openAndCloseTimeList":[[1740706200000,1740715200000],[1740718800000,1740729600000]],"volumeRatio":1.040789881394529,"optionData":{"bulkOrders":[{"symbol":"CSP.HK","call":true,"expireDate":1743091200000,"strike":"5.25","timestamp":1740720117788,"price":0.09,"volume":750,"amount":135000,"type":"*"},{"symbol":"CSP.HK","call":true,"expireDate":1743091200000,"strike":"5.50","timestamp":1740720047305,"price":0.06,"volume":750,"amount":90000,"type":"*"}]},"lotSize":2000,"spreadScale":0,"tradeCurrency":"HKD","optionSymbol":"CSP.HK","impliedVol":0.4325,"impliedVolPercentile":0.8293},"requestUrl":"/m/hq/s/01093","defaultTab":"news","newsList":[{"id":"2516560442","title":"石药集团只能往外跑了","url":"https://stock-news.laohu8.com/highlight/detail?id=2516560442","media":"财讯先锋","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516560442?lang=zh_cn&edition=full","pubTime":"2025-03-02 08:30","pubTimestamp":1740875431,"startTime":"0","endTime":"0","summary":"整体看来石药集团表现不及预期,同时集团在国际授权业务方面的新动向也备受关注。01不难发现,药品集采政策对石药集团的业绩产生了显著冲击。在二级市场上,石药集团股价表现相对低迷。石药集团今年频繁的对外授权动作,展现了这家老牌制药企业由仿转创的决心,虽然已经取得了一定进展,但面对仿制药业务下滑与创新药成长的过渡期挑战,石药集团仍需在经验积累中实现质的突破才行。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250302084528abe3ccad&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250302084528abe3ccad&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1993786604.SGD","IE00B5MMRT66.SGD","LU0326950275.SGD","LU1226288170.HKD","LU1951186391.HKD","LU0140636845.USD","LU1008478684.HKD","BK1515","LU1226287529.USD","IE00BZ08YS42.EUR","BK1191","LU1226287875.USD","LU0072913022.USD","LU1152091168.USD","IE00BZ08YR35.GBP","IE00BZ08YT58.USD","BK1521","IE0008369823.USD","LU0067412154.USD","01093","LU1960683339.HKD","LU1807302812.USD","LU0880133367.SGD","IE0008368742.USD","IE00B543WZ88.USD","LU0501845795.SGD","LU1226288253.USD","SG9999004220.SGD","LU1152091754.HKD","IE00B031HY20.USD","LU1226287792.SGD"],"gpt_icon":0},{"id":"2514349360","title":"石药集团:注射用西罗莫司(白蛋白结合型)于中国获突破性治疗认定","url":"https://stock-news.laohu8.com/highlight/detail?id=2514349360","media":"格隆汇资讯","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514349360?lang=zh_cn&edition=full","pubTime":"2025-02-28 18:00","pubTimestamp":1740736834,"startTime":"0","endTime":"0","summary":"格隆汇2月28日丨石药集团公告,集团开发的注射用西罗莫司获中华人民共和国国家药品监督管理局授予突破性治疗认定,拟定适应症为单药用于恶性血管周围上皮样细胞瘤。此前已有口服制剂的西罗莫司获批上市,主要适用于预防接受肾移植患者的器官排斥。同时,该产品拓展了西罗莫司的应用领域,有望实现治疗mTOR信号通路驱动的一系列疾病。恶性PEComa国内尚无标准治疗,存在未被满足的临床需求。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250228180046989630f0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250228180046989630f0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0140636845.USD","LU1152091754.HKD","LU1226287875.USD","IE00B543WZ88.USD","IE00BZ08YR35.GBP","LU0067412154.USD","LU1008478684.HKD","LU1226288170.HKD","LU1226287529.USD","IE0008369823.USD","LU0501845795.SGD","IE0008368742.USD","SG9999004220.SGD","LU1226287792.SGD","01093","LU1951186391.HKD","LU1152091168.USD","BK1191","LU1960683339.HKD","BK1521","LU1226288253.USD","LU1807302812.USD","LU0880133367.SGD","LU1993786604.SGD","IE00B5MMRT66.SGD","IE00B031HY20.USD","IE00BZ08YS42.EUR","LU0072913022.USD","IE00BZ08YT58.USD","LU0326950275.SGD","BK1515"],"gpt_icon":0},{"id":"2514349325","title":"石药集团(01093):注射用西罗莫司(白蛋白结合型)于中国获突破性治疗认定","url":"https://stock-news.laohu8.com/highlight/detail?id=2514349325","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514349325?lang=zh_cn&edition=full","pubTime":"2025-02-28 18:00","pubTimestamp":1740736805,"startTime":"0","endTime":"0","summary":"智通财经APP讯,石药集团 发布公告,集团开发的注射用西罗莫司获中华人民共和国国家药品监督管理局授予突破性治疗认定,拟定适应症为单药用于恶性血管周围上皮样细胞瘤。此前已有口服制剂的西罗莫司获批上市,主要适用于预防接受肾移植患者的器官排斥。同时,该产品拓展了西罗莫司的应用领域,有望实现治疗mTOR信号通路驱动的一系列疾病。恶性PEComa国内尚无标准治疗,存在未被满足的临床需求。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1256254.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IE00B5MMRT66.SGD","SG9999004220.SGD","LU1226287875.USD","LU0140636845.USD","LU1807302812.USD","IE00BZ08YR35.GBP","LU1226287792.SGD","BK1515","LU1226288170.HKD","LU1152091754.HKD","IE0008368742.USD","LU1008478684.HKD","LU1993786604.SGD","BK1521","LU1226287529.USD","LU0326950275.SGD","LU1152091168.USD","BK1191","LU0067412154.USD","IE00B031HY20.USD","IE00BZ08YT58.USD","IE00BZ08YS42.EUR","IE0008369823.USD","LU1951186391.HKD","IE00B543WZ88.USD","LU0501845795.SGD","LU0072913022.USD","01093","LU1226288253.USD","LU0880133367.SGD","LU1960683339.HKD"],"gpt_icon":0},{"id":"2514460263","title":"【石药集团:注射用西罗莫司(白蛋白结合型)获突破性治疗认定】石药集团公告,集团开发的注射用西罗莫司(白蛋白结合型)获国家药品监督管理局授予突破性治疗认定,拟定适应症为单药用于恶性血管周围上皮样细胞瘤。该产品采用特殊技术将西罗莫司包裹于人血白蛋白中,克服口服制剂无法向靶部位递送足够浓度药量的缺点,实现了西罗莫司的注射给药,且无需激素预处理。同时,该产品拓展了西罗莫司的应用领域,有望实现治疗mTOR信号通路驱动的一系列疾病。","url":"https://stock-news.laohu8.com/highlight/detail?id=2514460263","media":"金融界","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514460263?lang=zh_cn&edition=full","pubTime":"2025-02-28 17:56","pubTimestamp":1740736580,"startTime":"0","endTime":"0","summary":"石药集团公告,集团开发的注射用西罗莫司(白蛋白结合型)获国家药品监督管理局授予突破性治疗认定,拟定适应症为单药用于恶性血管周围上皮样细胞瘤。该产品采用特殊技术将西罗莫司包裹于人血白蛋白中,克服口服制剂无法向靶部位递送足够浓度药量的缺点,实现了西罗莫司的注射给药,且无需激素预处理。同时,该产品拓展了西罗莫司的应用领域,有望实现治疗mTOR信号通路驱动的一系列疾病。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/02/28175648459695.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["SG9999004220.SGD","LU1226288253.USD","BK1521","LU1960683339.HKD","LU0501845795.SGD","LU0072913022.USD","IE0008369823.USD","LU1152091168.USD","LU0140636845.USD","LU1807302812.USD","LU1152091754.HKD","BK1515","LU0326950275.SGD","IE0008368742.USD","LU1993786604.SGD","BK1191","IE00BZ08YR35.GBP","LU1008478684.HKD","LU1226287529.USD","LU1226287875.USD","IE00BZ08YS42.EUR","LU1951186391.HKD","IE00B031HY20.USD","LU1226288170.HKD","IE00B543WZ88.USD","01093","IE00BZ08YT58.USD","LU0880133367.SGD","LU0067412154.USD","LU1226287792.SGD","IE00B5MMRT66.SGD"],"gpt_icon":0},{"id":"2514310079","title":"石药集团02月28日主力净流出5972万元 散户资金买入","url":"https://stock-news.laohu8.com/highlight/detail?id=2514310079","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514310079?lang=zh_cn&edition=full","pubTime":"2025-02-28 16:15","pubTimestamp":1740730509,"startTime":"0","endTime":"0","summary":"02月28日, 石药集团股价跌5.61%,报收4.71元,成交金额7.60亿元,换手率1.38%,振幅6.61%,量比1.04。石药集团今日主力资金净流出5972万元,上一交易日主力净流入4379万元。该股近5个交易日下跌5.39%,主力资金累计净流入7495万元;近20日主力资金累计净流入2.24亿元,其中净流入天数为12日。该股主力净额占比0.11%,港股市场排名2540/2648。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250228165320a2579bf1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250228165320a2579bf1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1807302812.USD","LU1008478684.HKD","LU0140636845.USD","LU1226288253.USD","LU0880133367.SGD","BK1515","SG9999004220.SGD","IE00B5MMRT66.SGD","IE00BZ08YR35.GBP","LU1226288170.HKD","IE00B031HY20.USD","LU1226287875.USD","IE00B543WZ88.USD","LU1951186391.HKD","LU0072913022.USD","LU1152091754.HKD","IE0008368742.USD","IE00BZ08YT58.USD","IE00BZ08YS42.EUR","IE0008369823.USD","LU0067412154.USD","BK1191","LU1226287792.SGD","LU0326950275.SGD","LU1993786604.SGD","BK1521","LU1960683339.HKD","LU1226287529.USD","01093","LU1152091168.USD","LU0501845795.SGD"],"gpt_icon":0},{"id":"2514439825","title":"港股异动 | 石药集团(01093)跌超4% 预计去年纯利同比减少约26% 多家大行下调其目标价","url":"https://stock-news.laohu8.com/highlight/detail?id=2514439825","media":"智通财经","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514439825?lang=zh_cn&edition=full","pubTime":"2025-02-28 11:57","pubTimestamp":1740715072,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,石药集团跌超4%,截至发稿,跌4.21%,报4.78港元,成交额3.19亿港元。消息面上,石药集团近日发盈警,预计集团截至2024年12月31日止年度的公司拥有人应占溢利将同比减少约26%。主要由于成药业务收入较同比减少约7%所致。野村表示,维持石药集团“买入”评级,目标价由7.02港元下调至6.48港元。该行调整对石药2024年至2026年收入预测,介乎下调1%至上调3%。同时上调去年及今年纯利预测19%及1%,但下调明年纯利预测12%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1255993.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01093"],"gpt_icon":0},{"id":"2514396436","title":"石药,遇到一个瓶颈","url":"https://stock-news.laohu8.com/highlight/detail?id=2514396436","media":"瞪羚社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514396436?lang=zh_cn&edition=full","pubTime":"2025-02-27 20:08","pubTimestamp":1740658080,"startTime":"0","endTime":"0","summary":"在近日发布盈利预警,同时出海方面,似乎遇到了一些瓶颈。这是石药梦开始的起点,而之后,EO-3021临床阶段陆续推进,对ELEV的股价影响堪称一波三折。2023年4月26日,EO-3021在ASCO大会发布poster引起广泛讨论,同日ELEV股价开始飙升。这是在所有患者均为后线治疗,且三分之一患者接受了三线以上治疗的情况下。该药具体的技术拆解可见文章《石药养出两颗金蛋》,2024年1月26日,该药首次公布临床试验数据,同日,股价一天时间翻了3.5倍左右。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250228124842abe03a83&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250228124842abe03a83&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1226287875.USD","LU0880133367.SGD","IE00B543WZ88.USD","IE00BZ08YS42.EUR","IE00BZ08YT58.USD","01093","SG9999004220.SGD","LU0067412154.USD","LU1152091168.USD","LU1951186391.HKD","LU0326950275.SGD","LU1226287792.SGD","LU1226288253.USD","IE00B5MMRT66.SGD","BK1521","LU1226288170.HKD","LU0140636845.USD","LU0501845795.SGD","LU1807302812.USD","IE00B031HY20.USD","LU0072913022.USD","LU1960683339.HKD","IE0008368742.USD","IE0008369823.USD","BK1515","BK1191","LU1152091754.HKD","LU1993786604.SGD","IE00BZ08YR35.GBP","LU1226287529.USD","LU1008478684.HKD"],"gpt_icon":0},{"id":"2514539879","title":"美银证券:维持石药集团“跑输大市”评级 降目标价至4港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2514539879","media":"和讯网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514539879?lang=zh_cn&edition=full","pubTime":"2025-02-27 17:38","pubTimestamp":1740649138,"startTime":"0","endTime":"0","summary":"热点栏目自选股 数据中心 行情中心资金流向模拟交易客户端美银证券发布研报称,维持 石药集团 “跑输大市”评级,目标价由4.1港元降至4港元,基于主要产品减价影响。该行调整对石药2024年至2026年收入预测,介乎下调1%至上调3%。美银指,石药集团发盈警,料去年纯利跌约26%,对比该行预测跌8%,扣除预付款影响则同比跌18%。在去年国家报销药品清单磋商中,丁苯(酞)注射及胶囊价格跌12.5%及3.6%,石药内生销售增长将面对进一步压力。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250227175039a256257b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250227175039a256257b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["01093"],"gpt_icon":0},{"id":"2514685878","title":"美银证券:维持石药集团(01093)“跑输大市”评级 降目标价至4港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2514685878","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514685878?lang=zh_cn&edition=full","pubTime":"2025-02-27 16:56","pubTimestamp":1740646603,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,美银证券发布研报称,维持石药集团“跑输大市”评级,目标价由4.1港元降至4港元,基于主要产品减价影响。该行调整对石药2024年至2026年收入预测,介乎下调1%至上调3%。美银指,石药集团发盈警,料去年纯利跌约26%,对比该行预测跌8%,扣除预付款影响则同比跌18%。在去年国家报销药品清单磋商中,丁苯(酞)注射及胶囊价格跌12.5%及3.6%,石药内生销售增长将面对进一步压力。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1255294.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01093","161027"],"gpt_icon":0},{"id":"2514823017","title":"港股异动 | 石药集团(01093)反弹近4% 大摩指其盈警对股价影响不大 看好今年新药销售业务","url":"https://stock-news.laohu8.com/highlight/detail?id=2514823017","media":"智通财经","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514823017?lang=zh_cn&edition=full","pubTime":"2025-02-27 15:29","pubTimestamp":1740641345,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,石药集团反弹近4%,截至发稿,涨3.94%,报5.01港元,成交额6.86亿港元。消息面上,石药集团此前发盈警,预计集团截至2024年12月31日止年度的公司拥有人应占溢利将同比减少约26%。大摩认为,由于传统药品价格在集中采购渠道内下跌,很大程度上投资者已预料其利润下跌,因此认为这次盈警对其股价影响不大。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1255179.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1162221912.USD","LU1152091754.HKD","LU0880133367.SGD","LU0795875169.SGD","LU1989772840.SGD","BK4504","LU2133065610.SGD","BK1515","IE00BZ08YT58.USD","LU0320765646.SGD","LU1732799900.SGD","LU0067412154.USD","LU1989772923.USD","BK4516","LU1226287529.USD","LU2028103732.USD","LU0326950275.SGD","BK4581","01093","LU0098860793.USD","LU0006306889.USD","LU0912757837.SGD","LU1732800096.USD","LU1226287875.USD","LU1993786604.SGD","LU2347655156.SGD","LU1363072403.SGD","IE00BZ08YR35.GBP","LU1226288253.USD","LU2023251221.USD","LU2089283258.USD","BK4585","LU0072913022.USD","LU0140636845.USD","LU0225283273.USD","IE00BZ1G4Q59.USD","LU1960683339.HKD","IE0008369823.USD","LU1951186391.HKD","LU0158827948.USD","IE00BKVL7J92.USD","LU1074936037.SGD","LU2089284900.SGD","LU0267386448.USD","LU1668664300.SGD","LU2111349929.HKD","SG9999004220.SGD","IE00B543WZ88.USD","LU1807302812.USD","LU0501845795.SGD"],"gpt_icon":0},{"id":"2514412188","title":"【大行评级|美银:下调石药集团目标价至4港元 销售增长在药品减价中受压】美银指,石药集团发盈警,预计去年纯利跌约26%,对比该行预测跌8%,扣除预付款影响则按年跌18%。成药销售按年跌约7%,对比该行预估的扣除预付款后跌9%。公司称收入及净利润下跌主要由津优力及多美素于京津冀3+N联盟药品集采中价格下跌,以及玄宁没有在国家第八批集采中中选,导致抗癌治疗及心向管治疗领域收入按年跌28%及15%。 该行指,多美素去年12月于国家第十批集采中中选,但面临另一轮减价。在去年国家报销药品清单磋商中,丁苯(酉太)注射及胶囊价格跌12.5%及3.6%,石药内生销售增长将面对进一步压力。该行调整对石药2024年至2026年收入预测,介乎下调1%至上调3%。同时上调去年及今年纯利预测19%及1%,但下调明年纯利预测12%。该行将其目标价由4.1港元降至4港元,维持“跑输大市”评级,基于主要产品减价影响。","url":"https://stock-news.laohu8.com/highlight/detail?id=2514412188","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514412188?lang=zh_cn&edition=full","pubTime":"2025-02-27 13:55","pubTimestamp":1740635733,"startTime":"0","endTime":"0","summary":"成药销售按年跌约7%,对比该行预估的扣除预付款后跌9%。在去年国家报销药品清单磋商中,丁苯(酉太)注射及胶囊价格跌12.5%及3.6%,石药内生销售增长将面对进一步压力。该行调整对石药2024年至2026年收入预测,介乎下调1%至上调3%。同时上调去年及今年纯利预测19%及1%,但下调明年纯利预测12%。该行将其目标价由4.1港元降至4港元,维持“跑输大市”评级,基于主要产品减价影响。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate","earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/02/27135548422260.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["01093"],"gpt_icon":0},{"id":"2514812274","title":"石药集团深陷困境,业绩大幅下滑,股价承压","url":"https://stock-news.laohu8.com/highlight/detail?id=2514812274","media":"新浪财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514812274?lang=zh_cn&edition=full","pubTime":"2025-02-27 10:33","pubTimestamp":1740623620,"startTime":"0","endTime":"0","summary":"集采冲击业绩,成药业务承压石药集团2024年业绩下滑的核心原因在于成药业务的营收下降,尤其是抗肿瘤和心血管治疗领域的产品受集采政策影响严重。股价持续低迷,市值缩水受业绩下滑、市场竞争加剧、人事动荡等多重因素影响,石药集团股价持续低迷。尽管石药集团在9月宣布50亿港元股份回购计划,但市场反应平淡,股价并未出现明显反弹。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250227104112a255a212&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250227104112a255a212&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IE00B5MMRT66.SGD","SG9999004220.SGD","LU1226287875.USD","LU0140636845.USD","LU1807302812.USD","IE00BZ08YR35.GBP","LU1226287792.SGD","BK1515","LU1226288170.HKD","LU1152091754.HKD","IE0008368742.USD","LU1008478684.HKD","LU1993786604.SGD","BK1521","LU1226287529.USD","LU0326950275.SGD","LU1152091168.USD","BK1191","LU0067412154.USD","IE00B031HY20.USD","IE00BZ08YT58.USD","IE00BZ08YS42.EUR","IE0008369823.USD","LU1951186391.HKD","IE00B543WZ88.USD","LU0501845795.SGD","LU0072913022.USD","01093","LU1226288253.USD","LU0880133367.SGD","LU1960683339.HKD"],"gpt_icon":0},{"id":"2514859976","title":"利润缩水近三成,石药如何挺过转型阵痛?","url":"https://stock-news.laohu8.com/highlight/detail?id=2514859976","media":"医药魔方","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514859976?lang=zh_cn&edition=full","pubTime":"2025-02-26 22:53","pubTimestamp":1740581580,"startTime":"0","endTime":"0","summary":" 对于此次预期净利减少,石药集团给出的解释是集采影响。 2022年开始,石药抗肿瘤和心血管业务核心产品受集采冲击明显,这两大业务下滑明显。 开启内外“求药”征程的同时,2023年,石药子公司新诺威更名为“石药创新”,这家石药集团下属的功能性食品及原料企业,正式转型为石药集团的创新药平台。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2025-02-26/doc-inemvssz8592682.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LU0140636845.USD","LU1960683339.HKD","LU1226287792.SGD","LU1152091754.HKD","LU1951186391.HKD","LU0072913022.USD","BK1515","LU0880133367.SGD","IE00B031HY20.USD","LU1226288253.USD","LU0067412154.USD","LU1152091168.USD","IE00BZ08YS42.EUR","IE00B543WZ88.USD","BK1521","01093","IE00BZ08YT58.USD","LU1226287529.USD","BK1191","IE0008369823.USD","LU1807302812.USD","LU1993786604.SGD","LU1008478684.HKD","IE00B5MMRT66.SGD","LU1226287875.USD","IE0008368742.USD","LU1226288170.HKD","IE00BZ08YR35.GBP","LU0326950275.SGD","SG9999004220.SGD","LU0501845795.SGD"],"gpt_icon":0},{"id":"2514888891","title":"港股收评:恒指收涨3.27% 中资券商股飙升","url":"https://stock-news.laohu8.com/highlight/detail?id=2514888891","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514888891?lang=zh_cn&edition=full","pubTime":"2025-02-26 16:22","pubTimestamp":1740558162,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["03908","07226","513600","IE00B543WZ88.USD","LU0823038988.USD","89618","LU0737861772.HKD","LU1328615791.USD","00941","LU0314109678.HKD","HHImain","600941","MCHmain","00688","09618","LU0384037296.USD","LU0819121731.USD","01093","HSCEI","SG9999001226.SGD","159582","YANG","BK4209","LU0593848301.USD","02833","03121","06881","LU0231483743.USD","LU0878005551.USD","HSI","80883","03690","601881","BK1583","MHImain","MPNGY","HSImain","LU0588546209.SGD","HSTECH","LU0251144936.SGD","399441","BK0261","LU1770034418.SGD","LU0315178854.USD","00960","JD","161726","00883","CHL"],"gpt_icon":0},{"id":"2514000684","title":"港股收盘,恒指收涨3.27%,科指收涨4.47%;中金(03908.HK)、中国银河(06881.HK)均涨超17%,龙湖集团(00960.","url":"https://stock-news.laohu8.com/highlight/detail?id=2514000684","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514000684?lang=zh_cn&edition=full","pubTime":"2025-02-26 16:08","pubTimestamp":1740557327,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["LU1188198961.HKD","BK1555","00883","HSCEI","513600","LU0359201885.HKD","LU0417516902.SGD","06881","BK1147","03908","600941","02833","MHImain","LU0128522157.USD","LU0456842615.SGD","LU0054450605.USD","LU0856984785.SGD","LU2097828631.EUR","HHImain","03121","89618","HSI","LU0149721374.USD","01093","07226","LU1366334651.USD","LU1880383440.USD","00960","601881","MPNGY","BK1536","HSImain","JD","IE00B543WZ88.USD","LU0348827113.USD","YANG","80883","03690","LU0348805143.USD","00941","LU1064130708.USD","00688","09618","CHL","LU0594300419.USD","MCHmain","LU2125910500.SGD","HSTECH","LU0708995583.HKD","LU0531971595.HKD"],"gpt_icon":0},{"id":"2514383848","title":"石药集团(1093.HK)盈警:预期2024年公司拥有人应占溢利同比减少约26%","url":"https://stock-news.laohu8.com/highlight/detail?id=2514383848","media":"IR之家","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514383848?lang=zh_cn&edition=full","pubTime":"2025-02-26 16:02","pubTimestamp":1740556957,"startTime":"0","endTime":"0","summary":"石药集团于2025年2月25日公告,截至2024年12月31日,预计集团截至2024年12月31日止年度的公司拥有人应占溢利将较截至2023年12月31日止年度约人民币58.73亿元的公司拥有人应占溢利减少约26%。石药集团拥有创新药、普药及原料药三大业务板块,主要从事医药及相关产品的开发、生产和销售。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250226184720a254bc9d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250226184720a254bc9d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1226287529.USD","IE0008369823.USD","LU1960683339.HKD","LU0140636845.USD","LU1226287875.USD","LU1152091168.USD","LU0880133367.SGD","IE00B5MMRT66.SGD","LU0067412154.USD","IE00BZ08YT58.USD","LU1951186391.HKD","SG9999004220.SGD","LU0326950275.SGD","LU0072913022.USD","LU1226288253.USD","LU1008478684.HKD","LU0501845795.SGD","IE00B031HY20.USD","BK1521","IE00B543WZ88.USD","LU1993786604.SGD","LU1226288170.HKD","IE0008368742.USD","IE00BZ08YS42.EUR","LU1807302812.USD","01093","LU1226287792.SGD","BK1515","BK1191","LU1152091754.HKD","IE00BZ08YR35.GBP"],"gpt_icon":0},{"id":"2514805007","title":"野村:维持石药集团(01093)“买入”评级 降目标价至6.48港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2514805007","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514805007?lang=zh_cn&edition=full","pubTime":"2025-02-26 15:45","pubTimestamp":1740555958,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,野村发布研报称,维持石药集团(01093)“买入”评级,目标价由7.02港元下调至6.48港元。该行将石药2024财年收入及盈利预测分别下调1.2%及6.4%,主要考虑到集团去年首九个月的药品销售疲弱,以及1亿美元的预定许可收入。另外,该行亦将石药2025财年收入及盈利预测分别上调2.1%及0.8%。野村表示,对石药2024财年的营收及盈利预测,较市场普遍预期低0.9%及0.8%;至于对2025财年的预测则高出0.1%及0.9%。该行亦指,理解石药在成熟业务方面面临压力,但认为公司最近对早期资产的对外授权部分,缓解了相关压力。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1254563.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01093"],"gpt_icon":0},{"id":"2514512001","title":"摩根士丹利:石药集团发盈警对股价影响不大 目标价6.8港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2514512001","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514512001?lang=zh_cn&edition=full","pubTime":"2025-02-26 15:21","pubTimestamp":1740554465,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["SG9999004220.SGD","LU1226288253.USD","BK1521","LU1960683339.HKD","LU0501845795.SGD","LU0072913022.USD","IE0008369823.USD","LU1152091168.USD","LU0140636845.USD","LU1807302812.USD","LU1152091754.HKD","BK1515","LU0326950275.SGD","IE0008368742.USD","LU1993786604.SGD","BK1191","IE00BZ08YR35.GBP","LU1008478684.HKD","LU1226287529.USD","LU1226287875.USD","IE00BZ08YS42.EUR","LU1951186391.HKD","IE00B031HY20.USD","LU1226288170.HKD","IE00B543WZ88.USD","01093","IE00BZ08YT58.USD","LU0880133367.SGD","LU0067412154.USD","LU1226287792.SGD","IE00B5MMRT66.SGD"],"gpt_icon":0},{"id":"2514001824","title":"野村下调石药目标价至6.48港元 上调2025财年盈测","url":"https://stock-news.laohu8.com/highlight/detail?id=2514001824","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514001824?lang=zh_cn&edition=full","pubTime":"2025-02-26 15:16","pubTimestamp":1740554172,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["IE00BZ08YT58.USD","LU0072913022.USD","SG9999004220.SGD","01093","LU1152091168.USD","IE00B543WZ88.USD","IE0008368742.USD","BK1521","BK1191","IE00BZ08YR35.GBP","LU1008478684.HKD","IE0008369823.USD","LU0067412154.USD","LU0880133367.SGD","IE00B031HY20.USD","IE00B5MMRT66.SGD","LU1226288170.HKD","LU1152091754.HKD","LU0140636845.USD","LU0326950275.SGD","LU1226288253.USD","LU1807302812.USD","BK1515","LU1226287792.SGD","LU1226287529.USD","LU1993786604.SGD","LU0501845795.SGD","LU1960683339.HKD","LU1951186391.HKD","LU1226287875.USD","IE00BZ08YS42.EUR"],"gpt_icon":0},{"id":"2514001010","title":"石药集团预计去年溢利减少约26%","url":"https://stock-news.laohu8.com/highlight/detail?id=2514001010","media":"新京报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514001010?lang=zh_cn&edition=full","pubTime":"2025-02-26 15:15","pubTimestamp":1740554131,"startTime":"0","endTime":"0","summary":"新京报讯2月25日,石药集团发布公告,预计集团2024年公司拥有人应占溢利将较2023年减少约26%。2024年的公司拥有人应占溢利减少主要由于成药业务收入较2023年减少约7%所致。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202502263330233696.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202502263330233696.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU1807302812.USD","LU1993786604.SGD","BK1521","LU1226288170.HKD","LU0072913022.USD","IE00B5MMRT66.SGD","LU1152091168.USD","IE0008369823.USD","LU1226287529.USD","IE00B543WZ88.USD","LU0880133367.SGD","LU1951186391.HKD","LU0067412154.USD","01093","IE0008368742.USD","BK1191","SG9999004220.SGD","LU1226287875.USD","LU0501845795.SGD","IE00BZ08YR35.GBP","IE00BZ08YS42.EUR","LU0326950275.SGD","LU1152091754.HKD","IE00B031HY20.USD","LU1226287792.SGD","LU1960683339.HKD","LU1008478684.HKD","BK1515","LU1226288253.USD","IE00BZ08YT58.USD","LU0140636845.USD"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.cspc.com.hk","stockEarnings":[{"period":"1week","weight":-0.0599},{"period":"1month","weight":0.0561},{"period":"3month","weight":-0.071},{"period":"6month","weight":0.0036},{"period":"1year","weight":-0.2096},{"period":"ytd","weight":-0.0146}],"compareEarnings":[{"period":"1week","weight":-0.0229},{"period":"1month","weight":0.1343},{"period":"3month","weight":0.1811},{"period":"6month","weight":0.2753},{"period":"1year","weight":0.3894},{"period":"ytd","weight":0.1436}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"石药集团有限公司是一家主要从事生产及销售药品的投资控股公司。该公司通过三个分部运营其业务。成药分部从事研发、生产及销售药品以及授权业务。原料产品分部从事生产及销售粉状维生素C及抗生素产品。功能食品及其他分部从事制造及销售功能食品产品(包括咖啡因食物添加剂、无水葡萄糖、阿卡波糖及维生素C含片)、提供医疗服务及其他。该公司的产品治疗领域包括神经系统、抗肿瘤、抗感染、心血管、呼吸系统、消化代谢等其他领域。该公司在国内和国外市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.516129,"avgChangeRate":0.005416},{"month":2,"riseRate":0.741935,"avgChangeRate":0.096729},{"month":3,"riseRate":0.466667,"avgChangeRate":0.019763},{"month":4,"riseRate":0.6,"avgChangeRate":0.056385},{"month":5,"riseRate":0.6,"avgChangeRate":0.038129},{"month":6,"riseRate":0.333333,"avgChangeRate":0.004615},{"month":7,"riseRate":0.354839,"avgChangeRate":0.000119},{"month":8,"riseRate":0.419355,"avgChangeRate":0.009776},{"month":9,"riseRate":0.516129,"avgChangeRate":0.002662},{"month":10,"riseRate":0.580645,"avgChangeRate":0.016021},{"month":11,"riseRate":0.451613,"avgChangeRate":0.005451},{"month":12,"riseRate":0.483871,"avgChangeRate":-0.01556}],"exchange":"SEHK","name":"石药集团","nameEN":"CSPC PHARMA"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.31.3","shortVersion":"4.31.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"石药集团(01093)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供石药集团(01093)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"石药集团,01093,石药集团股票,石药集团股票老虎,石药集团股票老虎国际,石药集团行情,石药集团股票行情,石药集团股价,石药集团股市,石药集团股票价格,石药集团股票交易,石药集团股票购买,石药集团股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"石药集团(01093)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供石药集团(01093)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}